Illinois Doctor Permanently Banned from Prescribing Controlled Drugs by DEA
Published Date: 4/25/2025
Notice
Summary
Dr. Syed Warsi from Illinois lost his medical and controlled substance licenses, so the DEA is officially revoking his registration to handle controlled substances. This means he can no longer prescribe or manage these drugs, effective immediately. If you’re a patient or partner, this change is final and means no more prescriptions from Dr. Warsi starting now.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Doctor barred from renewing or getting new registrations
The DEA revokes Dr. Syed Warsi's registration and also denies any pending applications to renew, modify, or obtain any additional DEA registration in Illinois. The Order (revoking Certificate No. BW8048022) is effective May 27, 2025.
Patients lose access to controlled drugs
DEA Certificate of Registration No. BW8048022 for Syed Warsi, M.D. is revoked, so patients of Dr. Warsi can no longer receive prescriptions or medical handling of controlled substances from him. The Order cites that Dr. Warsi's Illinois medical and controlled-substance licenses were suspended on July 13, 2022 and remain suspended, and the revocation becomes effective May 27, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-07173 — Notice of Public Meeting of the Arizona Advisory Committee
The Arizona Advisory Committee will meet online on May 2, 2025, to review and vote on an important opinion article about civil rights. This meeting affects anyone interested in Arizona’s civil rights issues and happens at 11 a.m. Arizona time. No money changes hands, but your voice and awareness matter!
Next: 2025-07175 — Liberty Pharmacy Inc.; Metro Care Pharmacy Inc.; Ritecare Pharmacy Inc.; United Pharmacy Upper Darby Inc.; Decision and Order
Four pharmacies in Philadelphia had their licenses suspended because they didn’t keep proper records of controlled substances, which could risk public safety. They didn’t ask for a hearing, so their registrations were officially revoked. This means they can’t legally handle these drugs anymore, effective immediately, impacting their business and customers.